{"id":"agn-151586","safety":{"commonSideEffects":[{"rate":null,"effect":"Testosterone suppression"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Lipid profile changes"}]},"_chembl":{"chemblId":"CHEMBL4303670","moleculeType":"Small molecule","molecularWeight":"424.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SARMs bind to the androgen receptor and promote anabolic effects in muscle and bone while minimizing androgenic side effects in other tissues. AGN-151586 is designed to provide the benefits of androgen therapy with improved selectivity and safety profile compared to traditional androgens.","oneSentence":"AGN-151586 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:10.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle wasting / sarcopenia"},{"name":"Hypogonadism (potential indication)"}]},"trialDetails":[{"nctId":"NCT05248880","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-03-08","conditions":"Glabellar Lines","enrollment":309},{"nctId":"NCT06834789","phase":"PHASE1","title":"A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-02-18","conditions":"Glabellar Lines","enrollment":132},{"nctId":"NCT06308198","phase":"PHASE3","title":"A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-03-29","conditions":"Glabellar Lines","enrollment":161},{"nctId":"NCT05248893","phase":"PHASE3","title":"A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-02-25","conditions":"Glabellar Lines","enrollment":986},{"nctId":"NCT05248867","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-03-16","conditions":"Glabellar Lines","enrollment":638},{"nctId":"NCT06151561","phase":"PHASE1","title":"Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-01-05","conditions":"Moderate to Severe Glabellar Lines","enrollment":24},{"nctId":"NCT04096326","phase":"PHASE2","title":"AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-09-26","conditions":"Glabellar Lines","enrollment":198},{"nctId":"NCT05496335","phase":"PHASE1","title":"A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-08-30","conditions":"Glabellar Lines","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AGN-151586","genericName":"AGN-151586","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-151586 is a small molecule being studied as a potential treatment for glabellar lines, with a phase 3 clinical trial (NCT05248867) comparing its efficacy to BOTOX and a placebo. The trial is assessing the safety and change in disease activity of intramuscular AGN-151586 injection in adult participants with glabellar lines.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}